Markets |
Wall St. rebounds from recent losses; deals help
DJ: 17,976.31 +263.65 NAS: 4,947.44
+56.22 S&P: 2,086.24
+25.22
(Reuters) - U.S. stocks
climbed more than 1 percent on Monday, rebounding from a sharp decline last
week, helped by deal activity in healthcare and a bounce in energy shares.
Also boosting investors' risk appetite, Chinese stocks surged to
seven-year highs, helped by hopes for more infrastructure spending and monetary
policy easing.
The Dow registered its biggest daily percentage gain since Feb.
3 and all 10 primary S&P500 sectors rose on the day, led by energy
.SPNY, which jumped 2.1 percent despite a slight decline in Brent and U.S. oil
prices.
"(The rally) sort of
seems to be global growth based right now: the Chinese economy is falling but
they're going to stimulate," said Uri Landesman, president of
Platinum Partners in New York.
M&A activity has helped boost equities, especially shares of
smaller companies, Landesman said. "That's been a theme of this market on
and off for a very long time."
On the deal front, OptumRx Corp, a unit of UnitedHealth Group (UNH.N),
agreed to buy pharmacy benefit manager Catamaran Corp (CTRX.O)(CCT.TO) in a
deal worth $12.78 billion. Shares of UnitedHealth, a Dow component, rose 2.5
percent to $121 while U.S. shares of Catamaran added 23.8 percent to $59.83.
The Dow Jones industrial
average .DJI rose 263.65 points, or 1.49 percent, to
17,976.31, theS&P 500 .SPX gained 25.22 points, or 1.22 percent,
to 2,086.24 and the Nasdaq Composite.IXIC added 56.22 points, or 1.15 percent, to
4,947.44.
Major indexes each lost more than 2 percent last week.
Uncertainty about Friday's jobs report and upcoming earnings,
which start in earnest in mid-April, could create volatility this week, with
the stock market closed for Good Friday.
The Nasdaq Biotech index .NBI rose 1.1 percent but
remains roughly 5 percent below a record high from earlier this month. The
group has recently been under pressure, with the index down 5.2 percent last
week in its biggest weekly decline in a year.
Teva Pharmaceutical (TEVA.TA) (TEVA.N) said
it would buy Auspex Pharmaceuticals Inc (ASPX.O) for
$3.5 billion. Ireland's Horizon Pharma Plc (HZNP.O) said
it would acquire Hyperion Therapeutics Inc (HPTX.O) in an
all-cash deal worth about $1.1 billion.
U.S. shares of Teva were up 0.9 percent at $62.52 while Auspex
added 41.5 percent to $100.36. Horizon rose 18.2 percent to $25.78 on the Nasdaq while Hyperion rose 7.6 percent to
$45.98.
Separately, Fujifilm Holdings Corp (4901.T)
agreed to acquire U.S. biotechnology firm Cellular Dynamics International
Inc (ICEL.O) for
$307 million. Cellular shares more than doubled in heavy trading.
About 5.8
billion shares changed hands on U.S. exchanges, below the 6.7 billion
daily average this month, according to BATS Global Markets.
Advancing issues outnumbered declining ones on the NYSE by 2,271
to 806, for a 2.82-to-1 ratio; on the Nasdaq,
1,856 issues rose and 881 fell, for a 2.11-to-1 ratio.
The S&P 500 posted 26 new 52-week highs and 1 new
low; the Nasdaq Composite recorded 110 new highs and
44 new lows.
No comments:
Post a Comment